Form 4: LENZ Therapeutics Director Receives Stock Option Grant

Director Frederic Guerard was granted 22,100 stock options in LENZ Therapeutics, Inc. as part of the company's director compensation policy.

Summary

• Director Frederic Guerard received a grant of 22,100 stock options on June 15, 2026.
• The options have an exercise price of $6.63 per share.
• The options are scheduled to vest in full on the earlier of June 15, 2027, or the date of the next annual meeting of stockholders, provided the director remains in service.
• The options expire on June 15, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• The value of the options is dependent on the future market performance of LENZ common stock.

Future Outlook

The options vest in one year, contingent upon the director's continued service to the company.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to incentivize board members and align their interests with long-term company performance.

Comparison to Industry Standards

• The grant of stock options to directors is consistent with standard compensation practices for small-cap biotechnology firms.
• The one-year cliff vesting schedule is a common retention mechanism for board members in the industry.

Corporate Governance

Stakeholder Impact

• Minor dilution impact on existing shareholders upon future exercise of options.

Next Steps

• Vesting of options on June 15, 2027, or the next annual meeting of stockholders.

Key Dates

Keywords

LENZ Therapeutics, LENZ, Form 4, Insider Trading, Stock Options, Director Compensation